title: Masitinib monotherapy in canine epitheliotropic lymphoma.
abstract: This study evaluated efficacy and side effects of masitinib in canine epitheliotropic lymphoma. Complete remission occurred in 2 of 10 dogs and lasted for median 85 days. Five dogs went into partial remission for median 60.5 days. Three pretreated dogs did not respond to therapy. Side effects occurred in six dogs and were mostly mild to moderate. Immunohistochemistry was available for eight dogs. KIT receptor was negative in all of them, six of eight lymphomas stained strongly positive for stem cell factor (SCF). platelet-derived growth factor (PDGF)-AA was weakly positive in two and negative in six. PDGF-BB was negative in four tumours, weakly positive in one and strongly positive in three. One was strongly positive for PDGF receptor (PDGFR)-β, seven were negative for that receptor. Five showed strong expression of PDGFR-α, two showed weak expression, one was negative. In conclusion, masitinib is effective in treating canine epitheliotropic lymphoma. But its effects are most likely not generated through the KIT receptor.
authors.affiliation: Medizinische Kleintierklinik, Ludwig Maximilians University Munich, Munich, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Holtermann
authors.affiliation: Department of Pathology and Diagnostic Investigations, College of Veterinary Medicine, Michigan State University, Diagnostic Center for Population and Animal Health, Lansing, MI, USA.
authors.forename: M
authors.initials: M
authors.lastname: Kiupel
authors.affiliation: Tierklinik Hofheim, Im Langgewann 9, 65719 Hofheim/Taunus, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Kessler
authors.affiliation: Department of Clinical Sciences of Companion Animals, Veterinary Faculty, Utrecht University, Utrecht, The Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Teske
authors.affiliation: Klinik für Kleintiere, Tierärztliche Hochschule Hannover, Hannover, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Betz
authors.affiliation: Medizinische Kleintierklinik, Ludwig Maximilians University Munich, Munich, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Hirschberger
mesh_terms: D000818:Animals; D000077214:Becaplermin; D001549:Benzamides; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D007150:Immunohistochemistry / Q000662:veterinary; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000662:veterinary*; D010880:Piperidines; D010982:Platelet-Derived Growth Factor / Q000032:analysis; D019009:Proto-Oncogene Proteins c-kit / Q000097:blood; D020574:Proto-Oncogene Proteins c-sis / Q000097:blood; D011725:Pyridines; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000097:blood; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000097:blood; D012074:Remission Induction; D013844:Thiazoles / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010880:Piperidines; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011725:Pyridines; D013844:Thiazoles; C075278:platelet-derived growth factor A; D000077214:Becaplermin; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha; D020797:Receptor, Platelet-Derived Growth Factor beta; C526575:masitinib
keywords: clinical pathology; oncology; small animal; tumour biology; tyrosine kinase